Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Hematol Oncol. 2018 Dec 5;37(1):96–102. doi: 10.1002/hon.2557

Table 2.

Dose Escalation Scheme and Dose-Limiting Toxicity.

Lurbinectedin Dose Number of Evaluable Patients/Number of Treated Patients Number of Patients with DLTs DLT
3.5 mg D1,8 3/3 0 ---
5.0 mg D1,8 3/4 0 ---
7.0 mg D1,8 7/11 2 (18.2%) Hyperbilirubinemia (grade 3, n=1)
Oral herpes (grade 3, n=1)
6.0 mg D1,8 3/6 1 (16.7%) Rhabdomyolysis (grade 4, n=1)
2.0 mg D1–3 4/5 0 ---
3.0 mg D1–3 2/6 0 ---
1.0 mg D1–3 3/4 0 ---
1.5 mg D1–3 2/3 0 ---

Data shown are n (%) of patients.